Tetrahydrobiopterin (BH 4 ) is an essential cofactor for synthesis of many neurotransmitters including serotonin. In serotonergic neurons, BH 4 is tightly regulated by GTP-cyclohydrolase I feedback regulator (GFRP). Given the pivotal role of the serotonergic system in mood disorders and selective serotonin reuptake inhibitors (SSRIs) antidepressant function, we tested the hypothesis that GFRP gene (GCHFR) variants would modify response to antidepressants in subjects with major depression. Two single nucleotide polymorphisms (rs7164342 and rs7163862) in the GCHFR promoter were identified and occurred as two haplotypes (GA or TT). A multiple regression analysis revealed that homozygous individuals for the TT haplotype were less likely to respond to the SSRI fluoxetine than to the tricyclic antidepressant nortriptyline (P ¼ 0.037). Moreover, the TT haplotype showed a reduced transcription rate in luciferase reporter gene assays, which may impact on BH 4 -mediated neurotransmitter production, thus suggesting a biological process through which GCHFR promoter variants might influence antidepressant response.
Introduction
Tetrahydrobiopterin (BH 4 ) is an essential cofactor for a number of enzymes including tryptophan hydroxylase, the rate-limiting step in the biosynthesis of the neurotransmitter serotonin 1 ( Figure 1 ). Furthermore, BH 4 can exert its effect on specific membrane receptors to stimulate directly the release of monoamine neurotransmitters, including serotonin. 2, 3 Several studies have examined the role of BH 4 in the etiology of mood disorders and its treatment. In a previous genetic investigation of the sepiapterin reductase (SPR) gene, the terminal enzyme in the de novo synthesis of BH 4 (Figure 1 ), we showed that variation in the SPR promoter influenced individual risk to mood disorders, as well as a having a potential role in response to selective serotonin reuptake inhibitors (SSRIs) in individuals with major depressive disorder (MDD). 4 Curtius et al. 5 showed that depressed patients treated with BH 4 showed a marked improvement in mood. Other studies have shown a relationship between BH 4 activity and antidepressants. [6] [7] [8] [9] [10] Several pharmacogenomic studies investigating mood-regulating drugs have shown altered expression in several components of the BH 4 pathway. [11] [12] [13] Together, this evidence supports a link between the BH 4 pathway and mood control, as well as in antidepressant function. Because BH 4 is essential for such important biological systems, the regulation of the enzyme which is rate limiting for BH 4 synthesis, GTP cyclohydrolase I (GTPCH; Figure 1 ), could be biologically, pathologically and therapeutically important. GTPCH is tightly regulated by GTP cyclohydrolase I feedback regulator (GFRP). [14] [15] [16] GFRP mediates feedback inhibition of GTPCH activity by BH 4 , and the inhibition by BH 4 is reversed by phenylalanine. 14 The GFRP gene is called GCHFR, and in the rat brain Gchfr expression is abundant in serotonergic neurons of the dorsal raphe nucleus, which releases serotonin to the rest of the brain, but is undetectable in other areas of the central nervous system including dopamine neurons of the midbrain or norepinephrine neurons of the locus coeruleus. 15 In this article, we investigated whether the GCHFR gene influenced antidepressant response in those with MDD. To examine this relationship, we sought to identify polymorphic variants of GCHFR gene and assess the functional significance of these variants and their association with relevant phenotypes.
Materials and methods

Search for GCHFR gene variants
Peripheral blood samples were collected from all the patients and genomic DNA was extracted by guanidine isothiocyanate extraction. 17 DNA was resuspended in 10 mmol l À1 Tris (pH 8.0)/1 mmol l À1 EDTA (0.5 ml) and stored at À20 1C.
The GCHFR gene is approximately 3.6 kb in length and consists of three exons. 18 The putative promoter region, open reading frame, intron-exon boundaries and untranslated regions of the GCHFR gene were amplified as four PCR fragments of 956, 830, 247 and 770 bp (Supplementary Table  S1 ). PCR was carried out in a total volume of 10 ml, containing 200 mmol l À1 dNTPs, 2 ml of Q solution (Qiagen GmbH, Hilden, Germany) for promoter fragments, 0.4 mM of each primer, 1.5 mmol l À1 MgCl 2 , 1 U of Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA, USA), 1 ml Platinum Taq reaction buffer and 20-100 ng of genomic DNA. Thermal cycling conditions were: 2 min at 96 1C (initial denaturation); 32 cycles of 15 s at 95 1C, 30 s at 60-65 1C, 40 s at 72 1C and a final extension of 2 min at 72 1C. The validity of the PCR fragments was determined by DNA sequence analysis of selected samples.
Reporter gene assays
Luciferase reporter gene assays were carried out as previously described. 19 Briefly, two cell lines were used, COS-7 (ATCC, no. CRL-1651) and RN46A. 20 COS-7 cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen, Auckland, New Zealand, catalog no. 11971) with 10% fetal calf serum in 75 cm 2 flasks at 37 1C (5% CO 2 ). RN46A cells Table S1 ). Amplified products were cloned into the firefly luciferase reporter vector pGL3-basic (Promega Corporation, Madison, WI, USA), using the BglII and HindIII sites. Constructs were confirmed by DNA sequencing and large-scale DNA preparations were carried out with AxyPrep Plasmid Miniprep Kit (Axygen Biosciences, Union City, CA, USA). Transfections of constructs into COS-7 and RN46A cells were performed in 24-well plates seeded at 5 Â 10 5 cells per well before transfection. Transfections were performed using FuGene (Roche Diagnostics GmbH, Mannheim, Germany) for COS-7 and Effectene (Qiagen) for RN46A, as per manufacturer's instructions. To control for variation in transfection efficiency among replicates, we cotransfected promoter constructs with the Renilla luciferase vector, pRL-TK (Promega Corporation). At 48 h after transfection, COS-7 and RN46A cells were harvested and firefly and Renilla luciferase chemiluminescence were measured using the Dual-Luciferase Reporter Assay System (Promega) on a PerkinElmer (Norwalk, CT, USA) VICTOR3 Wallac 1420 microplate reader. Promoter activity was calculated as the ratio of firefly to Renilla luciferase chemiluminescence. Each construct was tested in triplicate with at least three independent transfection experiments. To evaluate statistical significance, we used two-tailed t-test with 95% confidence interval on GraphPad Prism software (GraphPad, San Diego, CA, USA).
Study cohorts
Clinical trial sample. A total of 195 depressed outpatients were recruited for a long-term clinical study examining patterns and predictors of remission, response, recovery, relapse and recurrence. The clinical study began with a randomization to fluoxetine or nortriptyline. Full details of the patient characteristics, treatment protocol and 6-week outcome have been fully elucidated in an earlier study. 21 Of these 195 patients, 57% were women and the mean age was 31.6 year. Of the 100 patients randomized to fluoxetine, 86 completed an adequate 6-week antidepressant trial, whereas of the 95 randomized to nortriptyline, 68 completed an adequate 6-week antidepressant trial. Exclusion criteria were minimized but included a diagnosis of schizophrenia or bipolar I disorder, a principal current diagnosis of severe alcohol or drug dependence, severe antisocial personality disorder that was judged likely to interfere with cooperation with the research protocol or major physical illness. At the baseline assessment, patients were also required to have been free of all psychotropic medication for at least 2 weeks or five drug half-lives, except for an occasional hypnotic for sleep. This study was approved by the Canterbury Ethics Committee (Christchurch, New Zealand).
At the baseline assessment, patients were evaluated using the Structured Clinical Interview for Depression for DSM-IV (SCID), 22 and rated for depression severity on the Hamilton Depression Rating Scale (HDRS) 23 and Montgomery and Asberg Depression Rating Scale (MADRS) 24 . Patients were also assessed for axis II disorders, completed a range of selfreport questionnaires and had a detailed neurobiological assessment that included neuroendocrine, amino acid and plasma protein measures.
After the baseline assessment, patients were initially randomized to treatment with either fluoxetine or nortriptyline for a period of 6 weeks. If patients were randomized to fluoxetine the starting dosage was 20 mg per day. Clinicians had flexibility to adjust dosage down to 10 mg or up to 60 mg based on their clinical judgment. The usual dosing regime was 20 mg for 3 weeks, with an increase to 40 or 60 mg after 3 weeks if no or minimal response. At 6 weeks the fluoxetine doses ranged from 10 to 60 mg with a mean daily dosage of 28.1 mg. For patients randomized to nortriptyline, the protocol was to increase from 25 to 75 mg over the first three heights. After 1 week a blood level for nortriptyline was obtained, and clinicians then adjusted nortriptyline dosages based on clinical response, side effects and blood levels to try and ensure an optimal clinical trial over 6 weeks. At 6 week the daily nortriptyline doses ranged from 50 to 175 mg with a mean of 93.5 mg. During this time clinicians saw patients at least weekly and had flexibility to adjust dosages to try and achieve optimal clinical outcomes. For patients on nortriptyline, this included blood levels after 1 week and as clinically indicated. The HDRS and MADRS were repeated after 3 and 6 weeks on the initially prescribed antidepressant medication. The primary outcome was percentage improvement on the MADRS over the initial 6 weeks. The secondary outcome was a dichotomous response/nonresponse outcome based on achieving a X60% improvement on the MADRS.
Family sample. Antidepressant response in this study was rated retrospectively by participants with a history of MDD, who had been recruited for a family study of depression and personality disorder. Antidepressant response, in those who had received at least 20 mg daily for 6 weeks, was coded as 1 ¼ very good response, 2 ¼ good response, 3 ¼ slight response or 4 ¼ minimal, no or negative response. For this study, responders were those who rated their response as very good (1) or good (2) .
Participants for this family study were either probands, or siblings or parents of the probands. The recruitment strategy involved advertising for participants who had been treated for a depressive episode. Probands then identified living parents (preferably) and/or all siblings, with the objective of recruiting family trios. All consenting subjects were then seen by a trained interviewer, who was supervised by one research psychiatrist. The interview as based on the MiniInternational Neuropsychiatric Interview, 25 except that the SCID, 26 was used for the assessment of alcohol, and drug use and dependence. In addition to the Mini-International Neuropsychiatric Interview questions the Mood Disorder Questionnaire 27 was also used to assist with the diagnosis of bipolar disorders. Further details about the study are available in other studies. 19, 28 For this study, we have limited the eligible participants to those with a lifetime diagnosis of MDD (that is, excluding those with bipolar disorders, or those who used an SSRI for reasons other than depression), who received adequate trials of SSRI antidepressant drugs.
GCHFR genetic analysis
For GCHFR genotyping we developed a restriction fragment length polymorphism assay. Briefly, a 638 bp PCR product was generated as described above (Supplementary Table S1 ). Amplicon (4 ml) was digested in a total volume of 10 ml, with 1 U of Tsp509I restriction enzyme (New England Biolabs Inc., Ipswich, MA, USA), 1 ml of NEB Buffer 1 and incubated at 65 1C for 1 h. The digested fragments were separated on 3% agarose gels. The restriction pattern was GA/GA: 415, 223; GA/TT: 415, 299, 223, 116; TT/TT: 299, 223, 116.
Statistical analyses
The associations between the rs7164342 and rs7163862 polymorphisms and antidepressant response in the clinical trial were initially examined by multiple linear regression analysis with percent improvement on the MADRS as the dependent variable. Logistic regression was then used to examine categorical outcome response variables across both the clinical trial and the family study. It should be noted that of participants with MDD in the family study, some might have received an adequate trial of more than one of the SSRIs. Hardy-Weinberg equilibrium was calculated using SHEsis. 29 
Results
Search for GCHFR gene variants
The GCHFR gene was analyzed for DNA sequence variation in 24 unrelated individuals of Caucasian descent. The genetic screen included 1.3 kb of putative promoter, exonic regions including intronic boundaries and the 5 0 and 3 0 untranslated regions. The only variants observed in the regions screened were the adjacent À1012G4T and À1011A4T transversions of the putative promoter region. Although two existing independent dbSNP entries (rs7164342 and rs7163862) correspond to these variants, our analysis indicated these adjacent single nucleotide polymorphisms were in total linkage disequilibrium and behaved as one polymorphism with two haplotypes (GA and TT). This observation was based on the initial DNA sequence analysis of 24 individuals as well as genotyping of the two cohorts, totaling 734 individuals.
Functional analysis
To assess whether this polymorphism affected basal GCHFR promoter activity, we cloned the variant promoters into a luciferase reporter vector. Reporter gene assays of the two constructs showed a significant difference in basal transcription rate between the GA and TT haplotypes in both COS-7 and RN46A cells, with the TT haplotype showing lower expression levels than the GA haplotype (Figures 2a and b) .
Genetic analysis
To genotype this promoter polymorphism in clinical cohorts, we developed a restriction fragment length polymorphism assay. This assay was applied to all individuals in the trial study and the family study (n ¼ 156 and 578, respectively). The polymorphism was in Hardy-Weinberg equilibrium (P ¼ 0.08), with frequencies of 0.52 for the GA haplotype and 0.48 for the TT haplotype. We explored associations of promoter haplotypes with antidepressant response in individuals with MDD who were studied in the context of the randomized clinical trial of the antidepressants fluoxetine and nortriptyline. Table 1 shows the number of subjects by drug and haplotype, and their response to treatment. Multiple regression analysis revealed that there was no direct effect of drug (F ¼ 0.24, P ¼ NS) or of genotype (F ¼ 0.13, P ¼ NS), but that there was a significant drug Â genotype interaction (P ¼ 0.037). Thus individuals with the homozygous TT haplotype had a poorer response to fluoxetine and a better response to nortriptyline.
We next explored response in the family study. Table 2 shows the number of responders and nonresponders to fluoxetine, paroxetine and citalopram by haplotype. Logistic regression did not show any statistically significant effect of haplotype on SSRI response.
However, examination of the response rate in the SSRI trials across both the clinical trial and family study suggested that there were consistent effects (even if not individually statistically significant) for SSRI response between the homozygous GA and homozygous TT haplotypes. Table 3 shows the response rates in haplotype homozygotes across the drug trial and family study as well as the odds ratio (95% confidence intervals) of response. From this table it can be seen that the odds ratio is above one for nortriptyline, but consistently ranges from 0.24 to 0.71 for SSRIs. Although this is statistically significant in the drug trial for fluoxetine and approaches traditional levels of statistical significance for any SSRI trial in the family study, it is statistically significant for any SSRI trial across both studies, where there is a 76% response rate to any SSRI for those with homozygous GA haplotype, but only a 55% response rate to any SSRI in those with homozygous TT haplotype.
We also investigated whether there was association between GCHFR promoter haplotypes and clinical diagnosis in the family study, but none was apparent (data not shown).
Discussion
In this series of studies we have found in a randomized clinical trial in major depression that the homozygous TT haplotype pair was associated with a lower percentage improvement in depressive symptoms in those randomized to fluoxetine than in those randomized to nortriptyline. Furthermore, across both the clinical trial and the family study that there was a lower response to SSRIs in those with homozygous TT than the homozygous GA haplotype.
These findings suggest that GCHFR promoter variants may influence response to SSRIs. The GFRP protein tightly regulates BH 4 production, and in rat central nervous system this regulation appears to be restricted to serotonergic cells of the raphe nuclei. 15 Serotonin is implicated in many neuropsychiatric disorders including major depression. Furthermore, SSRIs are believed to exert their effect on raphe nuclei serotonin neurons, as well as at their targets. 30 Therefore a priori one would predict that GCHFR variants However, a larger study sample will be required to confirm these observations. We also investigated the consequences of GCHFR promoter haplotypes on transcriptional activity, using luciferase reporter gene assays. In the first instance we assessed promoter activity in COS-7, an African green monkey kidney cell line and subsequently in RN46A, an undifferentiated serotonergic cell line derived from rat raphe nuclei. We regarded the latter cell line to be of physiological relevance to mood disorders, as well as antidepressant response. The two reporter constructs representing either the GA or the TT haplotype showed similar expression profiles in both cell lines (Figures 2a and b) , where in each line the expression of the TT haplotype was significantly lower than the GA haplotype. In the association study, we observed a preponderance of homozygous TT haplotype pairs in patients with poor SSRI response. Lower GCHFR expression in patients with the TT haplotype may impact on response to SSRIs, although we do not have direct evidence for this suggestion. It would be of interest to investigate how patient haplotypes may impact directly on GFRP activity, but at present there is no routine method with which to measure GFRP protein activity in patient samples.
In conclusion, evidence is presented for a significant association between homozygous TT haplotypes in the GCHFR promoter and reduced response to the SSRI antidepressant drugs. Furthermore, the TT haplotype had a lower basal transcription rate than the GA haplotype in reporter gene assays performed in a serotonergic cell line, which suggests that patients with these haplotypes may have reduced levels of GFRP expression. Lowered expression of GCHFR, if it occurs in vivo, may lead to downstream effects on BH 4 -mediated neurotransmitter production, which in turn may influence response to SSRIs. These findings may also be of wider relevance to other physiological and pathological pathways that depend on GFRP activity.
